株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

世界の勃起不全治療薬市場:製品、地域別

Erectile Dysfunction Drugs Market - Growth, Trends, and Forecast (2019 - 2024)

発行 Mordor Intelligence LLP 商品コード 704961
出版日 ページ情報 英文 114 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=109.87円で換算しております。
Back to Top
世界の勃起不全治療薬市場:製品、地域別 Erectile Dysfunction Drugs Market - Growth, Trends, and Forecast (2019 - 2024)
出版日: 2019年05月01日 ページ情報: 英文 114 Pages
概要

世界の勃起不全治療薬市場は、2018年から2023年の予測期間を通じて約8%のCAGRで推移する見通しです。

当レポートでは、世界の勃起不全治療薬市場を調査し、市場の概要、製品・地域別の市場規模の推移と予測、市場動向、市場の成長要因および阻害要因の分析、市場機会、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 イントロダクション

  • 市場の定義

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 主な影響要因

第5章 市場の概要

  • 現在の市場シナリオ
  • ファイブフォース分析
    • 買い手の交渉力
    • 供給企業の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係

第6章 成長要因、阻害要因、市場機会、課題(DROC)

  • 市場の成長要因
    • 心疾患や糖尿病の合併症
    • 継続的な喫煙による罹患率の上昇
    • ストレスおよび座りがちな生活スタイル
  • 市場の阻害要因
    • 治療に対する患者の抵抗感
    • 服薬アドヒアランス不良
  • 市場機会
  • 主な課題

第7章 市場セグメンテーション

  • 製品別
    • バイアグラ(クエン酸シルデナフィル)
    • シアリス(タダラフィル)
    • レビトラ/スタキシン(バルデナフィル)
    • ステンドラ/スペドラ(アバナフィル)
    • ジーデナ(ウデナフィル)
    • ビタロス(アルプロスタジルクリーム)
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ
    • 南米

第8章 競合情勢

  • M&A分析
  • 合意、コラボレーション、パートナーシップ
  • 新製品の発売

第9章 主要企業

  • Apricus Biosciences, Inc.
  • Bayer AG
  • Cristalia Produtos Quimicos Farmaceuticos Ltd
  • Dong-A ST Co., Ltd.
  • Eli Lilly and Company
  • Meda Pharmaceuticals Inc.
  • Pfizer, Inc.
  • SK chemicals
  • Teva Pharmaceutical Industries Ltd.
  • VIVUS, Inc.

第10章 市場の将来展望

目次
Product Code: 62838

Market Overview

The major factors for the growth of the erectile dysfunction (ED) drugs market include the rising adoption of a sedentary lifestyle along with the associated stress, rising geriatric population, and comorbidity between erectile dysfunction and heart diseases, and diabetes.

Sedentary lifestyles, alcoholism, and smoking greatly increase the risk of erectile dysfunction. Increasing adoption of these poor lifestyle choices will lead to the overall growth of the erectile dysfunction drugs market. The rise in the number of ED cases can be correlated with the high growth of obesity, diabetes, and cardiovascular disorders. According to the World Health Organization, 17.7 million people died from cardiovascular diseases in 2015, representing 31% of all global deaths. Out of these deaths, 7.4 million deaths were due to coronary heart disease, ED could be an important marker for coronary artery disease (CAD). It has also been found that the onset of ED preceded the onset of CAD in almost 2/3 of the cases. Hypertension is also another major illness linked to erectile dysfunction and as reported by CDC in 2018, the prevalence of hypertension has grown at a considerable rate, to approximately 65 million people suffering from the condition in the US. The growing number of patients suffering from cardiovascular diseases is going to contribute to the rapidly growing pool of erectile dysfunction patients which in turn will lead to more patients seeking treatment hence boosting the overall growth of the market over the forecast period.

Scope of the Report

As per the scope of this report, erectile dysfunction is a very common condition and it can be defined as the inability to maintain an erection sufficient for sexual intercourse. The drugs used in the treatment of ED are covered under the scope of the report. The market is segmented by product type, distribution channel, and geography.

Key Market Trends

Retail Pharmacies is the Segment by Distribution Channel is expected to Dominate the Market

The retail pharmacies are expected to dominate the market owing to the easy availability of the erectile dysfunction drugs at retail stores. As per the data published by the Consumer Healthcare Products Association, there are more than 750,000 retail establishments in the US, both rural and urban consumers have access 24/7 to treatments for various conditions. Furthermore, several studies show that ED is increasingly prevalent with age and around 40% of men are affected at age 40. Thus, owing to the easy availability of the drug and rising cases of ED the market is expected to witness high growth over the forecast period.

North America is Expected to Dominate the Market

North America is expected to dominate the erectile dysfunction drugs market, owing to the rising geriatric population, increase in cases of ED and the presence of better healthcare infrastructure. According to the United States Census Bureau's Statistics as of 2017, the total number of people 65 and older exceeds 50 million, and between 2020-2030 the number of elderly is projected to increase by almost 18 million. Although much smaller in total size, the number of people aged 85 and older is expected to more than triple from an estimated 6 million today to nearly 20 million by 2060. The rise in geriatric population is expected to increase the number of patients suffering from ED, as it is very common in men above age 40. North America was followed by Europe in 2017. The availability of various ED drugs through over the counter (OTC) and online channels is a key factor for dominance of these regions. The presence of online pharmacy stores is a blessing in disguise for several patients who are conscious about visiting a retail pharmacy store to purchase ED and other sexual wellness products.

Competitive Landscape

The market studied is a fragmented market owing to the presence of the various small and large market players. Some of the market players are Apricus Biosciences, Inc., Bayer AG, Eli Lilly and Company, Ferring Pharmaceuticals, GlaxoSmithKline plc., Metuchen Pharmaceuticals, LLC, Pfizer Inc., S.K. Chemicals Co. Ltd., Teva Pharmaceutical Industries Ltd., and VIVUS, Inc.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Adoption of a Sedentary Lifestyle Along with the Associated Stress
    • 4.2.2 Rising Geriatric Population
    • 4.2.3 Comorbidity between Erectile Dysfunction and Heart Diseases, and Diabetes
  • 4.3 Market Restraints
    • 4.3.1 Reluctance of Patients to Seek Treatment
    • 4.3.2 Poor Patient Adherence to ED Drugs
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product
    • 5.1.1 Viagra (sildenafil citrate)
    • 5.1.2 Cialis (Tadalafil)
    • 5.1.3 Levitra/Staxyn (vardenafil)
    • 5.1.4 Stendra/Spedra (avanafil)
    • 5.1.5 Zydena (udenafil)
    • 5.1.6 Vitaros (Alprostadil Cream)
    • 5.1.7 Others
  • 5.2 By Distribution Channel
    • 5.2.1 Hospital Pharmacies
    • 5.2.2 Retail Pharmacies
    • 5.2.3 Online Pharmacies
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 US
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 UK
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Apricus Biosciences, Inc.
    • 6.1.2 Bayer AG
    • 6.1.3 Eli Lilly and Company
    • 6.1.4 Ferring Pharmaceuticals
    • 6.1.5 GlaxoSmithKline Plc
    • 6.1.6 Metuchen Pharmaceuticals, LLC
    • 6.1.7 Pfizer Inc.
    • 6.1.8 S.K. Chemicals Co. Ltd.
    • 6.1.9 Teva Pharmaceutical Industries Ltd.
    • 6.1.10 VIVUS, Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top